Diabetes Care
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Blomgren, K. B.
Right arrow Articles by Wiholm, B. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Blomgren, K. B.
Right arrow Articles by Wiholm, B. E.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Diabetes Care 25:298-302, 2002
© 2002 by the American Diabetes Association, Inc.

Epidemiology/Health Services/Psychosocial Research
Original Article

Obesity and Treatment of Diabetes With Glyburide May Both Be Risk Factors for Acute Pancreatitis

Kerstin B. Blomgren, RN1, Anders Sundström, BA2, Gunnar Steineck, MD, PHD3 and Bengt E. Wiholm, MD, PHD, FRCP(L)2,4

1 Pharmacoepidemiological Unit, Department of Clinical Pharmacology, Karolinska Institute, Huddinge University Hospital, Stockholm, Sweden
2 Medical Product Agency, Uppsala, Sweden
3 Clinical Cancerepidemiology, Stockholm City Council and Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden
4 Karolinska Institutet, Stockholm, Sweden

OBJECTIVE—To evaluate risk factors, notably drugs, for acute pancreatitis.

RESEARCH DESIGN AND METHODS—A population-based case-control study was conducted of 1.4 million inhabitants, aged 20–85 years, of four regions in Sweden between 1 January 1995 and 31 May 1998. A total of 462 case subjects were hospitalized in surgery departments for their first episode of acute pancreatitis without previous gallbladder disease. A total of 1,781 control subjects were randomly selected from a population register. Information was obtained from case records and through telephone interviews.

RESULTS—A total of 27 case subjects (6%) and 55 control subjects (3%) had prevalent diabetes. A total of 53 case subjects (11%) and 130 control subjects (7%) had a BMI >30 kg/m2. Use of glyburide had a crude odds ratio (OR) of 3.2 (95% CI 1.5–5.9), and in a multivariate logistic regression adjusted for covariates, the OR for use of glyburide was 2.5 (1.1–5.9). BMI had a continuous OR of 1.2 (1.1–1.4) per 5 units of BMI. The relative risk for hospitalization longer than 14 days or treatment in an intensive care unit was 2.4 (1.1–5.4) among patients with a BMI >30 kg/m2 when compared with patients with a BMI between 20 and 25 kg/m2.

CONCLUSIONS—Use of glyburide and obesity may both be risk factors for acute pancreatitis. Obesity is associated with an extended hospitalization time in subjects with acute pancreatitis.

Abbreviations: ICU, intensive care unit • OR, odds ratio


Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2002 by the American Diabetes Association.